R&D Highlights of 2015 - The Five Big Drug Stories Of The Year
This article was originally published in Scrip
2015 may have been the year when immune-oncology dominated the R&D headlines, but there were other products that caught Scrip's readers' interest during the 12 months for reasons both good and bad – here are five of the most-read topics.
You may also be interested in...
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.